SCHEMBL2066409

SCHEMBL2066409

Cc1nn(CC(=O)N2CCOCC2)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.55
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 3/20 0.44
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
FGFR2 P21802 2/20 0.41
FGFR3 P22607 2/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
FLT3 P36888 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
FKBP1A P62942 1/20 0.41
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15230715 0.83 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL22648259 0.75 CNR2 (0.38) SMN1; SMN2MAPTPOLBFGFR2FLT3
SCHEMBL521747 0.74 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL13103451 0.74 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL18377855 0.74 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL24156797 0.74 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL1665180 0.74 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2ATP53
SCHEMBL16845639 0.74 IRAK4 (0.61) IRAK4FLT3
SCHEMBL16845669 0.74 IRAK4 (0.57) SMN1; SMN2TP53IRAK4FLT3
SCHEMBL2067169 0.73 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 SMN1; SMN2 2076/4885ALDH1A1 2405/4885MEN1 3285/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 SMN1; SMN2 2076/4885ALDH1A1 2405/4885MEN1 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.